Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Current Evidence and Future Insights
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (1 April 2024) | Viewed by 265
Special Issue Editors
Interests: infection; immunology of infectious diseases; vaccines; tropical diseases; emerging infectious diseases; infectious disease diagnostics and treatment
Special Issues, Collections and Topics in MDPI journals
Interests: infection; tropical diseases; emerging infectious diseases; infectious disease diagnostics and treatment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
COVID-19 vaccination, a treatment which minimizes the rates of infection and major complications of te disease, is amongst the most effective plans for controling the current COVID-19 pandemic. However, in addition to these benefits of vaccinations, at the beginning of 2021, a prothrombotic syndrome was encountered for the first time in some of the recipients of the ChAdOx1 CoV-19 vaccine. Since the hallmark of this syndrome was the development of thrombosis and/or thrombocytopenia between 5–30 days after vaccination (ChAdOx1 nCoV-19 or Ad26.COV2.S), it was named vaccine-induced immune thrombotic thrombocytopenia (VITT). Therefore, some concerns were raised about an increased risk of VITT among individuals who had received COVID-19 vaccines. Until now, the exact mechanism being VITT remains unclear. Additionally, there are still a great many questions left unanswered regarding the risk factors, diagnosis, and management of this syndrome. On these bases, it is clear that there are several essential trending topics remaining to work on in terms of COVID-19 VITT. The Special Issue aims to identify and fill important knowledge gaps including potential mechanisms, clinical implications, diagnosis, and management of COVID-19 VITT.
Dr. Soheil Ebrahimpour
Dr. Mostafa Javanian
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2
- COVID-19
- vaccines
- VITT
- cerebral venous thrombosis
